Chronic Idiopathic Constipation Market Research Report – Forecast to 2027

Chronic Idiopathic Constipation Market Research Report: By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), Treatment (Drugs), End-User (Hospitals & Clinics, Diagnostic Centers) -Forecast Till 2027

ID: MRFR/Pharma/4475-HCR | | Region: Global | 100 pages

Chronic Idiopathic Constipation Market Overview:


The chronic idiopathic constipation market trends are expected to rise at a good rate and attain excellent market revenue after the outbreak of the pandemic on the market during the ongoing forecast period of 2021-2028. The chronic idiopathic constipation market is likely to grow at a global CAGR that accounts for 7% and is likely to be attained by the end of the forecast period in 2028.


Chronic idiopathic constipation is understood and referred to as an extremely widespread functional bowel disorder that causes distress amongst millions of people around the globe, especially during the forecast period. Some of the major features of the market that are contributing to the growing number of patients that are suffering from chronic idiopathic constipation include a sedentary lifestyle, a severe decrease in the intake of dietary fibers, and the rise in usage of anti-inflammatory agents.


COVID 19 Analysis


The COVID-19 pandemic has broken the internet and market trends and has circulated new opportunities and challenges. The pandemic is an incomparable global public health emergency. The arrival of the pandemic has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period that will be ending in 2028. The research analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report discusses that the outbreak of the pandemic has forced people to bring about a change in their lifestyle and consumer preferences. The pandemic has further forced the global governments and public sector to take important steps like lockdown and strict measures that will impact the market and the demand that might result in losses during the forecast period that will be ending in 2028.


The government and market players are understanding the need to return to normalcy to keep the market functioning with the rising competition in the global market premises. The chronic idiopathic constipation market trends are expected to rise with the enhanced research and development initiatives that are prevailing in the global market premises amid the duration of the current forecast period of 2021-2028.


Market Dynamics


Drivers


Major factors that are expected to boost the growth of the chronic idiopathic constipation market in the forecast period are the rise in the aging population. The rising ease and accessibility of over-the-counter drugs for chronic idiopathic constipation is further anticipated to propel the growth of the global market. On the other hand, the accessibility of substitute treatments is further projected to impede the growth of the chronic idiopathic constipation market in the timeline period that will be ending in 2028.


Restraints


However, the chronic idiopathic constipation market size is witnessing a decrease in the diverse need for healthcare expenditure in a few advancing and developing countries that might further challenge the growth of the chronic idiopathic constipation market as expected shortly, especially during the ongoing forecast period that will be ending in 2028.


Technology Analysis


The target audience across the world is known to have accepted living a sedentary lifestyle alongside a severe degree of decrease in the intake of dietary fibers that are impacting the people and hence, giving rise to the chronic idiopathic constipation market. Also, the market trends show that there has been a rising degree of use for anti-inflammatory agents and agencies. The technological availability is welcoming the investments from various domestic and international companies and governments that are likely to provide the market with a good fortune and expansion rate during the ongoing forecast period that will be ending in 2028.


Study Objectives



  • The global chronic idiopathic constipation market study aims to have a deep study of the global market functions before and after the novel coronavirus had hit the international market scale. The report aims to have an idea about the market dynamics like the opportunities and drivers that will help the market during the forecast period that will be ending in 2028. The market report also aims to develop an understanding of the restraints that might challenge the market from growing as per the predictions.

  • The market report also discusses the basis of the global market segmentation through which the market is functioning in a series of global locations for meeting the rising needs of the target audience that is spread in the prominent places for the market and hence, help the market grow as per the potential revenue that has been forecasted for the period that will be ending in 2028.

  • The chronic idiopathic constipation market report aims to have an idea about the rising market competition that is a result of the trends and developments that have been in the way of rising and expansion in the global industry during the ongoing forecast period and further, help the investors make better decisions.


Segment Overview


The chronic idiopathic constipation market dynamics predict a good fortune for the market amid the rising market trends. The market is being recorded to perform at an excellent scale based on the global segmentation that is as follows:


Based on the diagnosis


The chronic idiopathic constipation market is segmented based on the diagnosis and includes blood tests, sigmoidoscopy, colonoscopy, balloon expulsion test, anorectal manometry, colonic transit study, defecography, and others.


Based on the treatment


The chronic idiopathic constipation market is segmented based on the treatment and includes drugs and surgery. Drugs have further been segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics, antiulcer, lubiprostone (amitiza), and linaclotide (linzess), misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) alongside others like Onabotulinumtoxin A (also called botulinum toxin type A or Botox).


Based on the end-user industries


The chronic idiopathic constipation market is segmented based on the end-user industries and includes hospitals, gastroenterology clinics, diagnostic centers, and others.


Regional Analysis


The North American chronic idiopathic constipation market has been segmented into two domestic regions, namely, North America and South America. The North American region, being the largest market, is witnessing major growth trends during the forecast period ending in 2028. The growth is mainly driven due to the substantial increase in the prevalence of chronic constipation and the growing investment in the healthcare departments and infrastructure. Also, the U.S., as a part of North America is the largest market in the North American region owing to the huge and evolving presence of a large number of market players who are indulged in the manufacturing of medications for constipation.


Competitive Landscape


The global rise in the market premises during the ongoing forecast period of 2021-2028 is because of the splendid record and performance of the prominent players of the market that are stated as follows:



  • Pfizer Inc (U.S.)

  • Progenics Pharmaceuticals (U.S.)

  • GlaxoSmithKline (U.K.)

  • Sucampo Pharmaceuticals Inc (U.S.)

  • Ironwood Pharmaceuticals (U.S.)

  • Sanofi (France)

  • Salix Pharmaceuticals Ltd (U.S.)

  • Bayer (Germany)


Recent Developments



  • According to a report that has been circulated by the World Gastroenterology Organization, approximately 35 to 40 % of the world’s total population is known to be suffering from acute or chronic GI complications. There has been an increasing number of patients recorded who are having GI diseases and disorders due to changes in their dietary patterns. This is the major factor that will be driving the chronic idiopathic constipation market towards growth in the forecast period.

  • According to reports that have been circulated from Allergan and Ironwood Pharmaceuticals, Inc. the major symptoms of constipation are infrequent stools or having a bowel movement less than three times a week), difficulty in passing stools. This also includes straining to have a bowel movement, but not completely emptying bowels after a movement. The hard or lumpy stools, gas pain, abdominal discomfort, and others are some of the prominent signs of people having constipation issues that are on a rise.

  • The European chronic idiopathic constipation market trends exhibit good growth with an increasing emphasis on the diagnosis followed by the treatment of GI diseases and others. Moreover, Germany and the U.K. are the major contributors to the growth as a part of the global market. Additionally, the has been an increasing degree of expenditure in healthcare by major countries in the European region that accelerates the growth of the market.


Report Overview


The chronic idiopathic constipation market report is focusing on the market developments for the period that will lead the way of the market towards growth during the forecast period that will be ending in 2028. The market report covers the basis of the market segmentation and the rising market potential to meet the needs of the target audience during the period.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   7.4% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.) and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing number of patients having GI diseases
  • Disorders due to change in dietary pattern


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Chronic idiopathic constipation market is expected to expand at 7.4% CAGR from 2020 to 2027.

    Early detection of GI diseases at a preventive stage is the primary driver of the global chronic idiopathic constipation market.

    Low awareness of the treatment is the major factor expected to impede the global chronic idiopathic constipation market growth.

    The Americas is expected to dominate the global chronic idiopathic constipation market till 2027 due to large number of cases of chronic constipation.

    Pfizer Inc, Salix Pharmaceuticals Ltd, Bayer, Sucampo Pharmaceuticals Inc, GlaxoSmithKline, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Synergy Pharmaceuticals, Boehringer Ingelheim GmbH, Progenics Pharmaceuticals, F. Hoffmann-La Roche AG, Daewoong Co. Ltd., Actavis, Synergy Pharmaceuticals, Inc., Ferring International Center S., and Sanofi are prominent players of the global chronic idiopathic constipation market.